AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33356905 — intervention group
Group type: COMPARATOR
Intervention: Active sham stimulation
Number of subjects: 0
Study 33971155 — intervention group
Group type: EXPERIMENTAL
Intervention: Voclosporin (23.7 mg twice daily)
Number of subjects: 357
Study 33971155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study 33971155 — intervention group
Group type: EXPERIMENTAL
Intervention: Voclosporin
Number of subjects: 357
Study 35123525 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted syringe technique
Number of subjects: 54
Study 35123525 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 54
Study 32891074 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Based Learning (PBL)
Number of subjects: 2
Study 32891074 — intervention group
Group type: COMPARATOR
Intervention: Traditional instruction (Control)
Number of subjects: 2
Study 36200397 — intervention group
Group type: EXPERIMENTAL
Intervention: Coach2Move
Number of subjects: 292
Study 36200397 — intervention group
Group type: COMPARATOR
Intervention: UCP
Number of subjects: 292
Study 33022048 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief behavioral treatment for insomnia (BBTI)
Number of subjects: 91
Study 33022048 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation training (PMRT)
Number of subjects: 91
Study 32992927 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor multisurface terrain training
Number of subjects: 22
Study 34915273 — intervention group
Group type: EXPERIMENTAL
Intervention: Total carbohydrate (30-g increment)
Number of subjects: 1279
Study 34915273 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic load (20-unit increment)
Number of subjects: 1279
Study 34155908 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavelet-based method for estimating time-varying functional connectivity (TVFC)
Number of subjects: 400
Study 34155908 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavelet-based method for estimating TVFC
Number of subjects: 400
Study 34155908 — intervention group
Group type: EXPERIMENTAL
Intervention: MVPR method
Number of subjects: 400
Study 32928298 — intervention group
Group type: EXPERIMENTAL
Intervention: MA&R in addition to standard mental healthcare
Number of subjects: 128
Study 32928298 — intervention group
Group type: COMPARATOR
Intervention: Standard mental healthcare alone
Number of subjects: 128
Study 36008827 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated KRT initiation
Number of subjects: 2927
Study 33972265 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive Intelligent Control of Oxygenation (PRICO)
Number of subjects: 27
Study 33972265 — intervention group
Group type: COMPARATOR
Intervention: Routine Manual Control (RMC)
Number of subjects: 27
Study 32815759 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 µg hepatitis B vaccine (IM20 group)
Number of subjects: 50
Study 32815759 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 µg hepatitis B vaccine (IM60 group)
Number of subjects: 50
Study 35461248 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (VR)
Number of subjects: 42
Study 35461248 — intervention group
Group type: COMPARATOR
Intervention: Control group (no VR)
Number of subjects: 42
Study 32297449 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 0
Study 32297449 — intervention group
Group type: COMPARATOR
Intervention: Background-medication-based individualized comparators (BMICs) including enalapril, valsartan, or placebo
Number of subjects: 0
Study 33592641 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training with agility ladder (n=10)
Number of subjects: 20
Study 33592641 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 20
Study 32750571 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 8240
Study 32750571 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 8240
Study 32750571 — intervention group
Group type: COMPARATOR
Intervention: Heparin lead-in
Number of subjects: 8240
Study 32750571 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall anticoagulation treatment
Number of subjects: 8240
Study 35590185 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental alcohol prime
Number of subjects: 80
Study 35590185 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe sex message prime
Number of subjects: 80
Study 35590185 — intervention group
Group type: EXPERIMENTAL
Intervention: Either or both prime(s)
Number of subjects: 80
Study 33511549 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-operative treatment
Number of subjects: 0
Study 33511549 — intervention group
Group type: COMPARATOR
Intervention: Operative treatment
Number of subjects: 0
Study 33097380 — intervention group
Group type: EXPERIMENTAL
Intervention: Random nucleus location within the cell; calculated S-values using Geant4-DNA for mono energetic electrons (10–100 keV) with varying nucleus positions.
Number of subjects: 0
Study 34808130 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetoscopic endoluminal tracheal occlusion
Number of subjects: 287
Study 34808130 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetoscopic endoluminal tracheal occlusion with early balloon insertion
Number of subjects: 287
Study 34808130 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 287
Study 33940665 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous-containing fluoride dentifrice
Number of subjects: 100
Study 33940665 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride dentifrice (negative control)
Number of subjects: 100
Study 34252302 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-ranging rifapentine
Number of subjects: 662
Study 32198409 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF group (82 patients)
Number of subjects: 157
Study 32198409 — intervention group
Group type: COMPARATOR
Intervention: Control group (75 patients)
Number of subjects: 157
Study 35390539 — intervention group
Group type: EXPERIMENTAL
Intervention: Small bowel capsule endoscopy (SBCE) in patients with surgically altered gastric anatomy
Number of subjects: 207
Study 35390539 — intervention group
Group type: COMPARATOR
Intervention: Control group (native gastric anatomy)
Number of subjects: 207
Study 33884731 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier cream
Number of subjects: 64
Study 33884731 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant
Number of subjects: 64
Study 33884731 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier cream/micellar water
Number of subjects: 64
Study 33884731 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant/micellar water
Number of subjects: 64
Study 33884731 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 64
Study 34086294 — intervention group
Group type: EXPERIMENTAL
Intervention: War metaphor article
Number of subjects: 1128
Study 34086294 — intervention group
Group type: EXPERIMENTAL
Intervention: Change metaphor article
Number of subjects: 1128
Study 34086294 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 1128
Study 32440101 — intervention group
Group type: COMPARATOR
Intervention: Dupilumab 300mg subcutaneously administered, added to standard intranasal steroid mometasone furoate, duration of treatment: 24 weeks (SINUS-24) or 52 weeks (SINUS-52) with varying injection frequency.
Number of subjects: 0
Study 35450525 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-term low-dose melatonin
Number of subjects: 50
Study 35450525 — intervention group
Group type: COMPARATOR
Intervention: Exogenous melatonin supplements
Number of subjects: 50
Study 33340185 — intervention group
Group type: EXPERIMENTAL
Intervention: One-handed airway
Number of subjects: 60
Study 33340185 — intervention group
Group type: COMPARATOR
Intervention: Two-handed airway
Number of subjects: 60
Study 35798596 — intervention group
Group type: EXPERIMENTAL
Intervention: i-PRF group (intraarticular injection of injectable platelet-rich fibrin after arthrocentesis)
Number of subjects: 36
Study 35798596 — intervention group
Group type: COMPARATOR
Intervention: Control group (arthrocentesis procedure alone)
Number of subjects: 36
Study 35798596 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 33910617 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir 750 mg orally, three times daily for 14 days
Number of subjects: 120
Study 33910617 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment (control group)
Number of subjects: 120
Study 33910617 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Number of subjects: 120
Study 33865401 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printed tooth-borne tissue retraction devices (TRDs)
Number of subjects: 34
Study 33865401 — intervention group
Group type: COMPARATOR
Intervention: Conventional dental splints
Number of subjects: 34
Study 32169307 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with SSD (49 out of 140, 35%)
Number of subjects: 140
Study 32169307 — intervention group
Group type: COMPARATOR
Intervention: Participants without SSD
Number of subjects: 140
Study 35266669 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant + connective tissue graft
Number of subjects: 42
Study 35266669 — intervention group
Group type: COMPARATOR
Intervention: Implant
Number of subjects: 42
Study 33811868 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival pictograph first
Number of subjects: 839
Study 33811868 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability pictograph first
Number of subjects: 839
Study 33811868 — intervention group
Group type: COMPARATOR
Intervention: Level of description of NICU experiences
Number of subjects: 839
Study 32163106 — intervention group
Group type: COMPARATOR
Intervention: Weekly paclitaxel and nonpegylated liposomal doxorubicin (PM) with additional carboplatin (PMCb) for TNBC patients
Number of subjects: 914
Study 32163106 — intervention group
Group type: COMPARATOR
Intervention: Sequential intense dose‐dense epirubicin, paclitaxel, and cyclophosphamide (iddEPC)
Number of subjects: 914
Study 32163106 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (non-BRCA1/2 BC predisposition genes)
Number of subjects: 914
Study 32163106 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (ERBB2-negative, hormone receptor-positive BC)
Number of subjects: 914
Study 35289926 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised moderate-intensity aerobic and resistance training for 20 weeks followed by 32 weeks of unsupervised exercise (IMPROVE)
Number of subjects: 213
Study 35289926 — intervention group
Group type: COMPARATOR
Intervention: Support group plus Fitbit (SG+Fitbit) program for 20 weeks followed by 32 weeks of unsupervised activity
Number of subjects: 213
Study 35289926 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised moderate-intensity aerobic and resistance training
Number of subjects: 213
Study 35638392 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP)
Number of subjects: 0
Study 35638392 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33965683 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedical treatment
Number of subjects: 225
Study 33965683 — intervention group
Group type: COMPARATOR
Intervention: On-site treatment
Number of subjects: 225
Study 32842955 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam administered by a cardiologist
Number of subjects: 69
Study 32842955 — intervention group
Group type: COMPARATOR
Intervention: Propofol with anaesthesiologist assistance
Number of subjects: 69
Study 35616368 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 66
Study 35616368 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 66
Study 33473017 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine nasal drops (0.03%) administered six times daily (0.5 ml/dose) for 10 days
Number of subjects: 60
Study 33473017 — intervention group
Group type: COMPARATOR
Intervention: Standard supportive treatment
Number of subjects: 60
Study 33473017 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine nasal drops (0.03%)
Number of subjects: 60
Study 32703307 — intervention group
Group type: EXPERIMENTAL
Intervention: Dignity therapy (DT)
Number of subjects: 144
Study 32703307 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 144
Study 34775250 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness retreat
Number of subjects: 95
Study 34775250 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 95
Study 34347255 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium/Vilanterol
Number of subjects: 2444
Study 32448401 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/day of prednisolone (PSL)
Number of subjects: 90
Study 32448401 — intervention group
Group type: COMPARATOR
Intervention: 30 mg/day of prednisolone (PSL)
Number of subjects: 90
Study 35491532 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg daily
Number of subjects: 98
Study 35491532 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended treatment (except for SGLT2 inhibitors)
Number of subjects: 98
Study 32950737 — intervention group
Group type: EXPERIMENTAL
Intervention: Active case finding (ACF)
Number of subjects: 12566
Study 32950737 — intervention group
Group type: COMPARATOR
Intervention: Passive case finding (PCF)
Number of subjects: 12566
Study 35025687 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression plus chemotherapy
Number of subjects: 25
Study 35025687 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (control)
Number of subjects: 25
Study 34749770 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical low-dose calcipotriol ointment (0.05 µg/g)
Number of subjects: 6
Study 34749770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 32831097 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted neurocognitive hand therapy
Number of subjects: 33
Study 32831097 — intervention group
Group type: COMPARATOR
Intervention: Conventional neurocognitive therapy
Number of subjects: 33
Study 34470841 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary tuberculosis patients who experienced unplanned readmission within 31 days after discharge.
Number of subjects: 402
Study 34470841 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 402
Study 34470841 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >65 years
Number of subjects: 402
Study 34470841 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural residence
Number of subjects: 402
Study 34470841 — intervention group
Group type: EXPERIMENTAL
Intervention: Active smoking
Number of subjects: 402
Study 34470841 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease (COPD)
Number of subjects: 402
Study 34470841 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaving hospital against medical advice
Number of subjects: 402
Study 35170837 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimised minus lens (OML) therapy, power ranged between -1.00D and -6.25D
Number of subjects: 141
Study 35170837 — intervention group
Group type: COMPARATOR
Intervention: Observation group (corrected for any significant refractive error)
Number of subjects: 141
Study 35170837 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimised minus lens (OML) therapy
Number of subjects: 141
Study 32491278 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0
Study 32491278 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 0
Study 32491278 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body exercise
Number of subjects: 0
Study 32491278 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (general)
Number of subjects: 0
Study 35357762 — intervention group
Group type: EXPERIMENTAL
Intervention: HIAE - high‐intensity aerobic exercise
Number of subjects: 22
Study 35357762 — intervention group
Group type: EXPERIMENTAL
Intervention: AE+BFR - aerobic exercise with blood flow restriction
Number of subjects: 22
Study 35357762 — intervention group
Group type: COMPARATOR
Intervention: AE - aerobic exercise without BFR
Number of subjects: 22
Study 35357762 — intervention group
Group type: COMPARATOR
Intervention: CON - non-exercise control condition
Number of subjects: 22
Study 34587971 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA‐IM
Number of subjects: 552
Study 34587971 — intervention group
Group type: COMPARATOR
Intervention: Copper IUD
Number of subjects: 552
Study 34587971 — intervention group
Group type: COMPARATOR
Intervention: LNG implant
Number of subjects: 552
Study 34587971 — intervention group
Group type: COMPARATOR
Intervention: DMPA‐IM vs IUD
Number of subjects: 552
Study 34587971 — intervention group
Group type: COMPARATOR
Intervention: LNG implant vs IUD
Number of subjects: 552
Study 34587971 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 552
Study 32795983 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder+COM‐B Message intervention
Number of subjects: 34
Study 32795983 — intervention group
Group type: COMPARATOR
Intervention: Reminder‐only Message active control
Number of subjects: 34
Study 36454914 — intervention group
Group type: EXPERIMENTAL
Intervention: Circle of Security‐Parenting intervention (COS‐P)
Number of subjects: 78
Study 34544469 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led chronic pain management program (PAP)
Number of subjects: 0
Study 32101872 — intervention group
Group type: EXPERIMENTAL
Intervention: Hipcref diet intervention
Number of subjects: 128
Study 32101872 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 128
Study 35618247 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication intervention
Number of subjects: 537
Study 35618247 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 537
Study 32991991 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary isoleucine (Ile) at 12.5 g kg‐1 diet
Number of subjects: 630
Study 32991991 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary isoleucine (Ile) at 10.0-20.0 g kg‐1 diet
Number of subjects: 630
Study 32991991 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary isoleucine (Ile) at 10.0-12.5 g kg‐1 diet
Number of subjects: 630
Study 32991991 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary isoleucine (Ile) at 12.5-15.0 g kg‐1 diet
Number of subjects: 630
Study 32991991 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary isoleucine (Ile) at 10.0 and 12.5 g kg‐1 diet
Number of subjects: 630
Study 32991991 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary isoleucine (Ile) at 7.5-17.5 g kg‐1 diet
Number of subjects: 630
Study 32991991 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary isoleucine (Ile) at 10-12.5 g kg‐1 diet
Number of subjects: 630
Study 32991991 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary isoleucine (Ile) requirement
Number of subjects: 630
Study 32130593 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week jogging intervention
Number of subjects: 27
Study 35184255 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol 2g, q8h, for 7–14 days
Number of subjects: 84
Study 35184255 — intervention group
Group type: COMPARATOR
Intervention: Comparators (imipenem/cilastatin, meropenem, best available therapy)
Number of subjects: 84
Study 32126528 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha down-regulation neurofeedback training (NFT)
Number of subjects: 0
Study 32126528 — intervention group
Group type: COMPARATOR
Intervention: Sham-control group (random beta NFT)
Number of subjects: 0
Study 32126528 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha down-regulation NFT
Number of subjects: 0
Study 32126528 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 0
Study 36029952 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth Care intervention
Number of subjects: 1945
Study 36029952 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based Care intervention
Number of subjects: 1945
Study 34242627 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (behavioral and pelvic floor muscle therapies with midurethral sling surgery)
Number of subjects: 480
Study 34242627 — intervention group
Group type: COMPARATOR
Intervention: Midurethral sling surgery alone
Number of subjects: 480
Study 34242627 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (for women with Urogenital Distress Inventory irritative scores of ≥50th percentile)
Number of subjects: 480
Study 34242627 — intervention group
Group type: COMPARATOR
Intervention: Midurethral sling surgery alone (for women with Urogenital Distress Inventory irritative scores of ≥50th percentile)
Number of subjects: 480
Study 35083920 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnobirthing training
Number of subjects: 80
Study 34632507 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet continuous positive airway pressure (hCPAP)
Number of subjects: 188
Study 34632507 — intervention group
Group type: COMPARATOR
Intervention: High flow nasal cannula (HFNC)
Number of subjects: 188
Study 32757736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmetic camouflage (daily use for 12 weeks)
Number of subjects: 56
Study 32757736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmetic camouflage (total follow up)
Number of subjects: 56
Study 32757736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmetic camouflage (Phase I)
Number of subjects: 56
Study 32757736 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 56
Study 35633275 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 300 mg/day
Number of subjects: 34
Study 35633275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 35633275 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol
Number of subjects: 34
Study 34217031 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal lean angle (n = 43)
Number of subjects: 97
Study 34217031 — intervention group
Group type: EXPERIMENTAL
Intervention: Single lean angle (n = 26)
Number of subjects: 97
Study 33272025 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise monitored with telehealth
Number of subjects: 40
Study 33272025 — intervention group
Group type: COMPARATOR
Intervention: Centre-based exercise
Number of subjects: 40